| Literature DB >> 32042867 |
Qinghua Yang1, Shujuan Zhu1, Jin Xu1, Chenglin Tang2, Kaihui Wu1, Yanjun Wu1, Yiying Wang1, Huajun Sheng1.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease and its incidence will increase with age and is aggravating. The senile plaques (SPs) are one of three main pathological features in AD patients, which are formed by amyloid β-protein (Aβ) over-accumulation. β-amyloid precursor protein (APP), β-site APP cleavage (BACE1), and insulin degrading enzyme (IDE) proteins participate in the process of Aβ production and degradation. At present, the pathogenesis of AD is not yet clear and the current treatment methods can only relief the related symptoms of AD. The electro-acupuncture (EA) is a traditional Chinese medicine treatment combined the acupuncture and electrical stimulation and the treatment effect can also be controlled by transform the electrical frequency. Thus, in this experiment, we carried out behavioral test, immunohistochemistry (IHC), and Western Blot (WB) after different period treatments to the model mice by electro-acupuncturing "Baihui" and "Shenshu" acupoints in APP+/PS1+ double transgenic mice. It was found that the EA therapy can improve the ability of learning, memory and spatial exploration, and reduce the deposition of SPs in brain of AD model mice, and reduce the expressions of APP and BACE1, increase the expression of IDE protein. These results prompt that EA can effectively alleviate the pathological process of AD. We speculate that EA may play a comprehensive role in preventing the development of AD, considering the previous data.Entities:
Keywords: AD, Alzheimer's disease; APP, β-; Ach, aetylcholine; AchE, cholinesterase; Alzheimer's disease; Amyloid β-protein; Aβ, amyloid β-protein; ChAT, aetylcholine tansferase; EA, electro-acupuncture; Electro-acupuncture; IDE, insulin degrading enzyme; IHC, immunohistochemistry; SOD, superoxide dismutase; SPs, senile plaques; Senile plaques; Transgenic mice; amyloid precursor protein, BACE1; β-, site APP cleavage
Year: 2018 PMID: 32042867 PMCID: PMC6997572 DOI: 10.1016/j.gendis.2018.06.002
Source DB: PubMed Journal: Genes Dis ISSN: 2352-3042
Figure 1A Gene identification of experimental model mice. a,b,c were wild-type C57BL/6J mice, d,e,f were APP+/PS1+ double transgenic mice. B The comparison of the average escape latency time (s) by each group of mice in the covert platform experiment. *p < 0.05 and **p < 0.01 versus the control group, ###p < 0.001 versus the model group, ΔP < 0.05 versus the 2 periods of EA treatment group. C The comparison of the search path (cm) by each group of mice in the covert platform experiment. **p < 0.01 and ***p < 0.001 versus the control group, ##p < 0.01 and ###p < 0.001 versus the model group, ΔΔP < 0.01 versus the 2 periods of EA treatment group. D The comparison of the times of passing the hidden platform in the space exploration experiment. ***p < 0.001 versus the control group, ##p < 0.01 and ###p < 0.001 versus the model group, ΔP < 0.05 versus the 2 periods of EA treatment group (n = 6 in each group).
Figure 2A The changes of senile plaques (SPs) in the hippocampus. B The changes of SPs in the mice cortex. The stained SPs were indicated by the black arrow, a,e: the control group, b,f: the model group, c,g: the 2 periods of EA treatment group, d,h: the 3 periods of EA treatment group. C The number of staining for SPs in the hippocampus of each group. ****p < 0.0001 versus the control group, ##p < 0.01 and ####p < 0.0001 versus the model group, ΔΔP < 0.01 versus the 2 periods of EA treatment group. D The number of staining for SPs in the cortex of each group. ****p < 0.0001 versus the control group, ###p < 0.001 versus the model group (n = 6 in each group).
Figure 3A、B、C The expression of APP 、BACE1、IDE in the hippocampus of each group of mice. D, E, F The expression of APP, BACE1, DE in the cortex of each group of mice. a: the control group. b: the model group. c: the 2 periods of EA treatment group. d: the 3 periods of EA treatment group. G The level of APP, BACE1,IDE in the hippocampus was indicated by column chart of each group of mice. APP: ****p < 0.0001 versus the control group, ####p < 0.0001 versus the model group, ΔΔΔP < 0.001 versus the 2 periods of EA treatment group. BACE1: ****p < 0.0001 versus the control group, ##p < 0.01 and ###p < 0.001 versus the model group, ΔP < 0.05 versus the 2 periods of EA treatment group. IDE: ****p < 0.0001 versus the control group, ###p < 0.001 and ####P < 0.0001 versus the model group, ΔP < 0.05 versus the 2 periods of EA treatment group. H The level of APP 、BACE1、IDE in the cortex was indicated by column chart of each group of mice. APP: ***p < 0.001 versus the control group, #p < 0.05 and ##p < 0.01 versus the model group, ΔP < 0.05 versus the 2 periods of EA treatment group. BACE1: ***p < 0.001 versus the control group, #p < 0.05 versus the model group. IDE: ***p < 0.001 versus the control group, #p < 0.05 versus the model group, (n = 6 in each group).